InsiderTrades

Form 4 for GLUE Monte Rosa Therapeutics, Inc.

Accepted 2024-09-13 00:00:00 ET · period of report 2024-09-11 · accession 0000950170-24-106532 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
M 2024-09-13 2024-09-11+ GLUE Versant Ventures VI GP, L.P. 10% S - Sale $6.00 -567.2K 6.24M -8% -$3.40M

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-09-11 S D 541,897 $6.00 6,257,218 D — — (F1) The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $6.00 to $6.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. (F2) Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Each of Versant VI GP-GP and Versant VI GP may be deemed to share voting, investment and dispositive power over the shares held by Versant VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
2 Common Common Stock 2024-09-13 S D 9,269 $6.16 6,231,902 D — — (F4) The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $6.02 to $6.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. (F2) Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Each of Versant VI GP-GP and Versant VI GP may be deemed to share voting, investment and dispositive power over the shares held by Versant VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
3 Common Common Stock 2024-09-12 S D 16,047 $6.00 6,241,171 D — — (F3) The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $6.00 to $6.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. (F2) Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Each of Versant VI GP-GP and Versant VI GP may be deemed to share voting, investment and dispositive power over the shares held by Versant VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.